Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials

The New England Journal of Medicine
R M RobertsonJ A Oates

Abstract

Thromboxane A2 (TxA2), an arachidonic acid metabolite causing vasoconstriction and platelet aggregation, is a putative mediator of coronary-artery vasospasm. To determine whether platelet-released TxA2 causes coronary arterial vasospasm, we measured plasma thromboxane B2 (TxB2, the inactive hydration product of TxA2) in the radial-artery and coronary-sinus blood of seven patients and performed therapeutic trials of antiplatelet agents in nine. Although coronary-sinus TxB2 levels rose from the base line approximately fivefold with spontaneous ischemia, samples drawn early in ischemia showed no rise over base-line values. Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina"). Similarly, indomethacin had no effect on the frequency or duration of ischemia. TxA2 is unlikely to cause vasotonic angina, but it may be released during coronary vasospasm.

References

Nov 1, 1978·Japanese Heart Journal·Y UchidaS Murao
Feb 25, 1978·Lancet·D Robertson, J A Oates
Sep 1, 1979·Lancet·H SinzingerK Silberbauer
Jun 1, 1979·The American Journal of Cardiology·D RobertsonG C Friesinger
Oct 1, 1979·Southern Medical Journal·R M RobertsonD Robertson
Sep 1, 1978·The Journal of Experimental Medicine·I M GoldsteinG Weissmann
Sep 1, 1977·Analytical Biochemistry·F A FitzpatrickF F Sun
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Apr 12, 1973·The New England Journal of Medicine·P B OlivaR G Pluss
Oct 1, 1970·American Heart Journal·G R DagenaisC R Conti
Jan 8, 1981·The New England Journal of Medicine·F E PrestonC J Stoddard

❮ Previous
Next ❯

Citations

Jun 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·A M LeferJ B Smith
Jan 1, 1986·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·A HoeftG Hellige
Dec 1, 1984·Agents and Actions·F De ClerckR S Reneman
Sep 18, 1985·The American Journal of Cardiology·P Ganz, R W Alexander
Apr 16, 1985·European Journal of Pharmacology·D M LiG J Dusting
Sep 1, 1985·Prostaglandins, Leukotrienes, and Medicine·I A GreerC D Forbes
Aug 1, 1988·Journal of the American College of Cardiology·C de ZwaanH J Wellens
Nov 15, 1994·Journal of the American College of Cardiology·F W BärH J Wellens
Jan 1, 1989·Comparative Biochemistry and Physiology. C, Comparative Pharmacology and Toxicology·G S Bondy, P A Gentry
Jan 1, 1989·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·T J Hartney
Aug 1, 1985·Journal of the American College of Cardiology·H ShimokawaM Nakamura
Nov 1, 1985·Journal of the American College of Cardiology·T WargovichC R Conti
Jul 1, 1986·Journal of the American College of Cardiology·J T Shepherd, P M Vanhoutte
Jan 1, 1986·Journal of the American College of Cardiology·Y YuiC Kawai
Jan 1, 1986·Journal of the American College of Cardiology·G C Friesinger, R M Robertson
Feb 1, 1987·Journal of the American College of Cardiology·A Maseri
Oct 31, 1985·The New England Journal of Medicine·M B FormanR Virmani
Nov 28, 1985·The New England Journal of Medicine·J A CairnsM G Myers
Sep 13, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Shozo SuedaTadao Uraoka
Nov 1, 1991·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G AnfossiG Emanuelli
Mar 1, 1987·Blood Reviews·J Webster, A S Douglas
Nov 1, 1984·Clinical and Experimental Pharmacology & Physiology·M SturmR R Taylor
Jan 1, 1987·International Journal of Cardiology·F NumanoT Sasazuki
Jan 1, 1984·The American Journal of Emergency Medicine·J A CookP V Halushka
Nov 1, 1989·International Journal of Cardiology·T StefenelliJ Kaliman
Apr 1, 1989·Prostaglandins, Leukotrienes, and Essential Fatty Acids·G AnfossiG Emanuelli
Oct 1, 1983·International Journal of Cardiology·E R Burns, W H Frishman
Jan 1, 1988·Journal of Clinical Anesthesia·M Husain, J Moss

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.